Assessment of Clinical Outcome and Treatment Quality Under Adequate Use of Tolvaptan In Correction of Hyponatremia in Patients Hospitalized With Worsening Heart Failure and Hyponatremia

Trial Profile

Assessment of Clinical Outcome and Treatment Quality Under Adequate Use of Tolvaptan In Correction of Hyponatremia in Patients Hospitalized With Worsening Heart Failure and Hyponatremia

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Hyponatraemia
  • Focus Pharmacokinetics
  • Acronyms AQUATIC
  • Sponsors Korea Otsuka Pharmaceutical
  • Most Recent Events

    • 12 Jun 2017 Status changed from recruiting to discontinued.
    • 12 Jun 2017 Status changed from recruiting to discontinued.
    • 29 Nov 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top